Concepedia

Dose De-intensification

Dose De-Intensification is a dose modification strategy that reduces the intensity, frequency, or duration of a therapeutic regimen from its standard regimen, typically to mitigate treatment-related toxicity while preserving clinical efficacy.

25

Publications

1.2K

Citations

273

Authors

133

Institutions

Publications per year

2017–2026

12

Variants

Dose De-escalation

Parents

Publications

25

Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers

Hagop M. Kantarjian, Varsha Gandhi, Peter Kozuch et al. · Journal of Clinical Oncology · 2003 · 191 citations

, , +15

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

Lior H. Katz, Javier P. Gisbert, Beth Manoogian et al. · Inflammatory Bowel Diseases · 2012 · 132 citations · Full text

, , +13

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

Yves Pérel, Anne Auvrignon, Thierry Leblanc et al. · Leukemia · 2005 · 103 citations

, , +17

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Oleg Gluz, Ulrike Nitz, Nadia Harbeck et al. · Annals of Oncology · 2008 · 102 citations

, , +11

Naturally occurring tumors in dogs as comparative models for cancer therapy research.

K. Hahn, WarwickJ. Adams, Donita L. Frazier · PubMed · 1994 · 65 citations

, , +15

1–5 of 25

Authors

273

  1. DI
    David I. Rosenthal

    The University of Texas MD Anderson Cancer Center, United States

    2 publications · 96 citations

    2

    h-index

  2. NH
    Nadia Harbeck

    Ludwig-Maximilians-Universität München, Germany

    2 publications · 152 citations

    2

    h-index

  3. PM
    Paul M. Busse

    Massachusetts General Hospital, United States

    2 publications · 82 citations

    2

    h-index

  4. AS
    Adam S. Garden

    The University of Texas MD Anderson Cancer Center, United States

    2 publications · 96 citations

    2

    h-index

  5. SJ
    Steven J. Frank

    The University of Texas MD Anderson Cancer Center, United States

    2 publications · 96 citations

    2

    h-index

1–5 of 273

Institutions

133

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    3 h-index

    43 publications

    4.3K citations

  2. Inserm

    Paris, France

    2 h-index

    8 publications

    184 citations

  3. Düsseldorf University Hospital

    Düsseldorf, Germany

    2 h-index

    5 publications

    418 citations

  4. Emory University

    Atlanta, United States

    2 h-index

    2 publications

    93 citations

  5. University of Milan

    Milan, Italy

    2 h-index

    2 publications

    60 citations

  6. University of Michigan

    Ann Arbor, United States

    2 h-index

    3 publications

    314 citations

  7. Cleveland Clinic

    Cleveland, United States

    2 h-index

    13 publications

    396 citations

  8. University of North Carolina at Chapel Hill

    Chapel Hill, United States

    2 h-index

    3 publications

    144 citations

1–8 of 133

Venues

  1. Annals of Oncology

    3 publications · 212 citations

    3

    h-index

  2. PubMed

    Repository · 3 publications · 132 citations

    3

    h-index

  3. Journal of Clinical Oncology

    2 publications · 234 citations

    2

    h-index

  4. Oral Oncology

    2 publications · 22 citations

    2

    h-index

  5. Clinical and Translational Radiation Oncology

    CTRO · 2 publications · 71 citations

    2

    h-index

1–5